Please ensure Javascript is enabled for purposes of website accessibility

Pharma’s Diabetes War Escalates

By Dave Williamson - Updated Apr 7, 2017 at 12:29PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Today health-care analysts David Williamson and Max Macaluso look at one of the largest and most profitable segments of the pharmaceutical space: diabetes treatment. 
With the market growing rapidly, it's attracted a lot of attention from big pharma companies, and the pressure to improve treatments is heating up. 
Merck is attempting to hold on to market share for now, but Amalin's technology has the potential to upset the standing king. Ultimately, David thinks Merck will still be able to retain its throne but recognizes that the stakes are heating up.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$327.18 (0.76%) $2.47
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
$75.96 (-1.15%) $0.88
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$92.64 (0.24%) $0.22
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$10,986.00 (1.72%) $186.00
Alkermes plc Stock Quote
Alkermes plc
$31.43 (2.95%) $0.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.